Early Improvement in Scalp Hair Regrowth With Deuruxolitinib in Patients With Severe Alopecia Areata: Pooled Analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The user experienced hair regrowth with dutasteride and oral minoxidil from October 2025 to January 2026, but mid-scalp density decreased afterward despite continued treatment. Ketoconazole improves scalp condition, but stopping it worsens hair appearance.

The conversation is about a user's impressive hair recovery over 14 months using 0.5mg dutasteride, 5% topical minoxidil, saw palmetto shampoo, and occasional microneedling. The results are highly praised by others, with many expressing admiration and hope for similar outcomes.

A user shared their hair regrowth progress using oral Dutasteride, Biotin, and Minoxidil over nine months, reporting significant improvement without surgery. They emphasized the effectiveness of these medications and noted no side effects.